Cargando…

Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions

BACKGROUND: Although prophylaxis is a standard of care for young children in developed countries, known to reduce the severity of hemophilic arthropathy, older adults with existing arthropathy have not traditionally used prophylaxis. Recent studies have shown that adults with hemophilia A are increa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jackson, Shannon C, Yang, Ming, Minuk, Leonard, Sholzberg, Michelle, St-Louis, Jean, Iorio, Alfonso, Card, Robert, Poon, Man-Chiu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4331146/ https://www.ncbi.nlm.nih.gov/pubmed/25692030 http://dx.doi.org/10.1186/s12878-015-0022-8

Ejemplares similares

The impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B
por: Sun, Haowei (Linda), et al.
Publicado: (2021)

Individualized prophylaxis for optimizing hemophilia care: can we apply this to both developed and developing nations?
por: Poon, Man-Chiu, et al.
Publicado: (2016)

Extended half‐life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products
por: Teitel, Jerome, et al.
Publicado: (2021)

Hemophilia prophylaxis adherence and bleeding using a tailored, frequency‐escalated approach: The Canadian Hemophilia Primary Prophylaxis Study
por: Dover, Saunya, et al.
Publicado: (2020)

Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian real‐world, multicenter, retrospective study
por: Matino, Davide, et al.
Publicado: (2022)

Pharmacokinetic‐tailored approach to hemophilia prophylaxis: Medical decision making and outcomes
por: Croteau, Stacy E., et al.
Publicado: (2020)

Magnetic resonance imaging in boys with severe hemophilia A: Serial and end‐of‐study findings from the Canadian Hemophilia Primary Prophylaxis Study
por: Stimec, Jennifer, et al.
Publicado: (2021)

Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review
por: Yu, Jacky K., et al.
Publicado: (2019)

Optimization of prophylaxis for hemophilia A
por: Herbert, Robert D., et al.
Publicado: (2018)

Joining the patient on the path to customized prophylaxis: one hemophilia team explores the tools of engagement
por: Gue, Deborah, et al.
Publicado: (2015)

Clinical practice of personalized prophylaxis in hemophilia: Illustrations of experiences and benefits from two continents
por: Jackson, Shannon, et al.
Publicado: (2019)

Correction: Optimization of prophylaxis for hemophilia A
por: Herbert, Robert D., et al.
Publicado: (2018)

Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis
por: McEneny-King, Alanna, et al.
Publicado: (2017)

Adult idiopathic cholestasis: a condition more common in the Canadian Inuit?
por: Minuk, Gerald Y., et al.
Publicado: (2017)

Emerging therapies for hemophilia: controversies and unanswered questions
por: Arruda, Valder R., et al.
Publicado: (2018)

First analysis of 10-year trends in national factor concentrates usage in haemophilia: data from CHARMS, the Canadian Hemophilia Assessment and Resource Management System
por: Traore, A N, et al.
Publicado: (2014)

Hematuria in aging men with hemophilia: Association with factor prophylaxis
por: Qvigstad, Christian, et al.
Publicado: (2020)

Questions, Questions, Questions, and More Questions
por: Gillespie, Kay
Publicado: (2020)

Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors
por: Shapiro, Amy D., et al.
Publicado: (2022)

Serious bleeds in pediatric persons with hemophilia A on emicizumab prophylaxis
por: Garcia, Jessica, et al.
Publicado: (2023)

Thrombosis and Hemophilia: Little More Evidence, Much More Guidance
por: Hermans, Cedric
Publicado: (2023)

Hemophilia trials in the twenty‐first century: Defining patient important outcomes
por: Konkle, Barbara A., et al.
Publicado: (2019)

Effects of coagulation factor concentrate prophylaxis in moderate and severe hemophilia A patients at a single hemophilia center in Korea
por: Moon, Byung Suk, et al.
Publicado: (2013)

Significant reduction in hemarthrosis in boys with severe hemophilia A: The China hemophilia individualized low‐dose secondary prophylaxis study
por: Wu, Runhui, et al.
Publicado: (2021)

Management of surgery in persons with hemophilia A receiving emicizumab prophylaxis: data from a national hemophilia treatment center
por: Cohen, Omri, et al.
Publicado: (2023)

Adherence to treatment regimen and bleeding rates in a prospective cohort of youth and young adults on low-dose daily prophylaxis for severe hemophilia A
por: Mizrahi, Terry, et al.
Publicado: (2016)

Hemophilia without prophylaxis: Assessment of joint range of motion and factor activity
por: Wang, Michael, et al.
Publicado: (2020)

Damoctocog Alfa Pegol for Hemophilia A Prophylaxis: An Italian Multicenter Survey
por: Zanon, Ezio
Publicado: (2023)

Emicizumab prophylaxis for people with hemophilia A: Waste estimation and the Brazilian perspective
por: Camelo, Ricardo Mesquita, et al.
Publicado: (2023)

More Dengue, More Questions
por: Halstead, Scott B.
Publicado: (2005)

Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China
por: Gu, Congling, et al.
Publicado: (2022)

The Hemophilia Gene Therapy Patient Journey: Questions and Answers for Shared Decision-Making
por: Wang, Michael, et al.
Publicado: (2022)

Cost–utility analysis of prophylaxis versus treatment on demand in severe hemophilia A
por: Colombo, Giorgio L, et al.
Publicado: (2011)

The Perspectives of Adolescents and Young Adults on Adherence to Prophylaxis in Hemophilia: A Qualitative Study
por: Hoefnagels, JW, et al.
Publicado: (2020)

Cerebellar hematoma in severe hemophilia with inhibitor on emicizumab prophylaxis: a case report
por: Albattat, Sami, et al.
Publicado: (2023)

Adherence to hemophilia patients with prophylaxis: Veritas-Pro and psychometric properties adapted to Turkish
por: Mehrekula Demirci, Zuhal, et al.
Publicado: (2023)

Management of Severe Hemophilia A: Low-Dose Prophylaxis vs. On-Demand Treatment
por: Munawar Ali, Rabeea, et al.
Publicado: (2023)

Surgery and Prophylaxis with Susoctocog-Alfa in Acquired Hemophilia: Case Series and Literature Review
por: Sella, Carola, et al.
Publicado: (2023)

A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management
por: VALENTINO, L A, et al.
Publicado: (2012)

Cross-cultural adaptation of the CHO-KLAT for boys with hemophilia in rural and urban china
por: Wu, Runhui, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_iu6kprdpt37tnfgv52rm4d0ui6